Katherine Reeder-Hayes, MD, MBA, MSc, described the potential role of real-world evidence as a compliment to clinical trials as well as successful implementation of Big Data for real-world evidence generation.
A new study attempted to quantify the economic burden of early progression in patients with newly-diagnosed multiple myeloma.
A comparative effectiveness study examined clinical outcomes and costs after treatment with a febrile neutropenia therapy vs a biosimilar for patients with non-myeloid cancer undergoing chemotherapy.
Inadequate response to targeted immunomodulators for rheumatoid arthritis may lead to significantly higher economic burden, including higher health care resource utilization.
Real-World Study Determines Effectiveness of Targeted Therapy for Relapsed, Refractory B-Cell Malignancy
A recent study demonstrated the real-world effectiveness and tolerability of a targeted agent for the treatment of relapsed or refractory mantle cell lymphoma.
In a recent study, a combination therapy for the treatment of relapsed or refractory multiple myeloma proved to be as beneficial in routine clinical practice as it did in clinical trials used to support its approval.
Robin T Zon, MD, FACP, FASCO, and Bobby Daly, MD, MBA, discuss ASCO's recently published results of an evaluation of national pathway vendors against the Criteria for High-Quality Clinical Pathways.
Health care resource use and approaches to clinical management of advanced non-small cell lung cancer vary significantly in eight different countries.
The National Comprehensive Cancer Network has released the first-ever clinical practice guidelines addressing patients living with HIV who are diagnosed with cancer to help them receive safe and necessary treatment.
Commercial payers are spending almost twice as much on chemotherapy administered in hospital outpatient departments compared with therapy administered in physician offices.